Ouchida, T.; Isoda, Y.; Tanaka, T.; Kaneko, M.K.; Suzuki, H.; Kato, Y. Establishment of a Novel Anti-mouse CCR1 Monoclonal Antibody C1Mab-6. Preprints2023, 2023122059. https://doi.org/10.20944/preprints202312.2059.v1
APA Style
Ouchida, T., Isoda, Y., Tanaka, T., Kaneko, M.K., Suzuki, H., & Kato, Y. (2023). Establishment of a Novel Anti-mouse CCR1 Monoclonal Antibody C<sub>1</sub>Mab-6. Preprints. https://doi.org/10.20944/preprints202312.2059.v1
Chicago/Turabian Style
Ouchida, T., Hiroyuki Suzuki and Yukinari Kato. 2023 "Establishment of a Novel Anti-mouse CCR1 Monoclonal Antibody C<sub>1</sub>Mab-6" Preprints. https://doi.org/10.20944/preprints202312.2059.v1
Abstract
C-C motif chemokine receptor 1 (CCR1/CD191) is a member of G-protein-coupled receptors, and is expressed on myeloid cells, such as neutrophils and macrophages. Because the CCR1 signaling promotes tumor expansion in the tumor microenvironment (TME), the modification of TME is an effective strategy for cancer therapy. Although CCR1 is an attractive target for solid tumors and hematological malignancies, anti-CCR1 therapeutic agents have not been approved. Here, we established a novel anti-mouse CCR1 (mCCR1) monoclonal antibody (mAb), C1Mab-6 (rat IgG2b, kappa), using the Cell-Based Immunization and Screening (CIBS) method. Flow cytometry and Western blot analyses showed that C1Mab-6 recognizes mCCR1 specifically. The dissociation constant of C1Mab-6 for mCCR1-overexpressed Chinese hamster ovary-K1 was determined as 3.9×10-9 M, indicating that C1Mab-6 possesses a high affinity to mCCR1. These results suggest that C1Mab-6 could be a useful tool for targeting CCR1 in preclinical mouse models.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
